Amani Therapeutics

Amani Therapeutics is a privately-held company that develops medicines for serious psychiatric illnesses, including treatment-resistant schizophrenia, by advancing innovative fixed-dose combination therapies that reduce severe side effects and eliminate burdensome monitoring requirements. Amani Therapeutics was founded in 2025. Amani Therapeutics headquarters are located in New York, New York.

a company that develops medicines for serious psychiatric illnesses, including treatment-resistant schizophrenia, by advancing innovative fixed-dose combination therapies that reduce severe side effects and eliminate burdensome monitoring requirements, raises $25MM Series A from Undisclosed Investors.

a company that develops medicines for serious psychiatric illnesses, including treatment-resistant schizophrenia, by advancing innovative fixed-dose combination therapies that reduce severe side effects and eliminate burdensome monitoring requirements, raises $25MM Series A from RTW Investments.